Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: A European multicenter retrospective cohort study

Hawkes, C; Morris, J; Bavcar, S; Wilkie, C; Ray, S; Auquier, C; Benjamin, S; Masso, JB; Bottin, S; Davies, O; Desmas-Bazelle, I; Einhorn, A; Figueroa-Gonzalez, C; Holenova, K; Kritsotalaki, E; Peak, K; Smallwood, K; Treggiari, E; Valenti, P; de la Virgen, MG; Fournier, Q

Abstract

BackgroundPeripheral nodal B-cell lymphomas (PNBCL) represent the most common presentation of lymphomas in dogs. Multiagent CHOP (C = cyclophosphamide, H = hydroxydaunorubicin [Doxorubicin], O = Oncovin, P = prednisolone)-based chemotherapy protocols have been widely accepted as gold standard 1st-line treatment. CHOP-25 and CHOP-19 are most commonly prescribed but have never been directly compared. ObjectivesOur primary aim was to compare outcomes of dogs diagnosed with PNBCL, treated using a 1st-line CHOP-19 or CHOP-25 protocol. A secondary objective was to determine the impact of protocol-related variables on outcomes. AnimalsFive hundred two dogs from 16 European oncology referral centers. One hundred fifty-five dogs were treated with CHOP-19 and 347 dogs with CHOP-25. MethodsRetrospective, multicentric cohort study of dogs diagnosed with PNBCL between 2014 and 2021. ResultsThe 6-month, 1-year, and median progression-free survival (PFS) were 56.5% (95% confidence interval [CI], 49.2-65.0), 14.1% (95% CI, 9.4-21.0), and 196 days (95% CI, 176-233) with CHOP-19; and 56.4% (95% CI, 51.4-61.9), 17% (95% CI, 13.4-21.6), and 209 days (95% CI, 187-224) with CHOP-25. The 1-year, 2-year and median overall survival (OS) were 36.9% (95% CI, 29.7-46.0), 13.5% (95% CI, 8.6-21.1), and 302 days (95% CI, 249-338) with CHOP-19; and 42.8% (95% CI, 37.7-48.7), 15.4% (95% CI, 11.7-20.4), and 321 days (95% CI, 293-357) with CHOP-25. No significant difference in PFS and OS was found between the 2 protocols. Conclusions and Clinical ImportanceOur study confirmed similar outcomes for dogs with PNBCL treated with 1st-line CHOP-19 or CHOP-25. Both protocols therefore could be used as a standard of care in future trials.

Citation

Hawkes, C., Morris, J., Bavcar, S., Wilkie, C., Ray, S., Auquier, C., Benjamin, S., Masso, J., Bottin, S., Davies, O., Desmas-Bazelle, I., Einhorn, A., Figueroa-Gonzalez, C., Holenova, K., Kritsotalaki, E., Peak, K., Smallwood, K., Treggiari, E., Valenti, P., de la Virgen, M., & Fournier, Q. (2024). Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: A European multicenter retrospective cohort study. Journal of Veterinary Internal Medicine, https://doi.org/10.1111/jvim.17222

• Journal Article Type: Article
• Acceptance Date: Oct 1, 2024
• Online Publication Date: Oct 18, 2024
• Publication Date: 2024
• Deposit Date: Nov 14, 2024
• Publicly Available Date: Nov 14, 2024
• Journal: Journal of Veterinary Internal Medicine
• Print ISSN: 0891-6640
• Electronic ISSN: 1939-1676
• Publisher: Wiley Open Access
• Peer Reviewed: Peer Reviewed
• DOI: https://doi.org/10.1111/jvim.17222
• Keywords: canine; CHOP-19; CHOP-25; lymphoma; progression-free survival; CHEMOTHERAPY PROTOCOL; REMISSION DURATION; DOSE INTENSITY; CANINE; CYCLOPHOSPHAMIDE; CLASSIFICATION; ASSOCIATION; 15-WEEK; IMPACT; TIME